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BACKGROUND While second generation drug-eluting stents (DES)
promote more favorable vascular healing, biodegradable polymer con-
taining stentsmight have a yield in termsof duration of dual antiplatelet
therapy (DAPT) than durable polymer stents. We aimed to test whether
6-month DAPT would be non-inferior 12-month clinical and angio-
graphic outcome to 12-month DAPT with second generation DES, such
as biolimus-eluting stent (BES) and Zotarolimus-eluting stent (ZES).
METHODS We compare clinical events and angiographic data bet-
ween 6- and 12-month DAPT, and between BES and ZES stents.
Finally, 1,368 patients were randomly assigned. Optical coherence
tomography (OCT) at 6 month was performed in 30 patients of each
DES group. The primary end point was major adverse cardiac event
(MACE) at 12 months. The secondary end points are target vessel
failure, in-segment late loss (LL) at 12 months, and neointimal hy-
perplasia (NIH) and uncovered stent strut (USS) by OCT at 6 month.
RESULTS n ¼ 72 patients. The primary endpoint was not statistically
different between the 6- and 12-month DAPT (MACE: 3.5 vs.
2.5%;p¼0.33), between BES and ZES (MACE: 3.0 vs. 3.0%; p¼1.00). The
secondary end points also were not signiﬁcantly different between the
6- and 12-month DAPT in target vessel failure (1.3 vs. 0.6%; p¼0.25), LL
(mm) at 12 months (0.300.29 vs. 0.310.28, p¼0.61). Similar results
showed between BES and ZES in target vessel failure (0.8 vs. 1.1%;
p¼0.58), LL (mm) at 12 months (0.320.29 vs. 0.310.27, p¼0.61). OCT
at 6 month revealed that mean NIH thickness (mm) of BES and ZES were
81.657.1, 61.939.6, respectively (p¼0.13), and USS percentage (%) of
BES and ZESwere quite few, as 2.45.3, 3.05.2, respectively (p¼0.64).
CONCLUSION We suggest that 6 month DAPT might be suggestively
safe after 2nd generation DES implantation based on clinical, angio-
graphic, and favorable result of 6 month OCT sub-study.DRUG-ELUTING STENTS (TCTAP A-002)
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BACKGROUND The safety and performance of the Absorb Bio-
resorbable Vascular Scaffold (Absorb) (Abbott Vascular, Santa Clara,
CA) have been demonstrated in the ABSORB Cohort A, B, and EXTEND
trials. Results from the ABSORB Cohort B trial showed 4-year MACE of
10.1%, with no scaffold thrombosis reported. ABSORB EXTEND sought
to gain experience with the Absorb in a large population and in
different geographies, including the AsiTCTAP A-Paciﬁc region.
METHODS ABSORB EXTEND is a prospective, single-arm, open-label
clinical study that enrolled a total of 812 subjects from 56 global sites.
Patients with lesions  28 mm in length and reference vessel diameter
of 2.0 - 3.8 mm (as assessed by on-line QCA or IVUS) were included.Treatment of a maximum of two de novo native coronary artery le-
sions, each in a different epicardial vessel, and long lesions using
planned scaffold overlap were permitted.
RESULTS In the ﬁrst 450 patients enrolled, the mean age at implant
was 62 years. Major comorbidities included previous MI (29%), un-
stable angina (33%), and diabetes mellitus (27%). Lesion locations
were 44%, 26%, and 30% for LAD, LCX and RCA respectively. The
mean RVD was 2.58 mm and mean lesion length was 11.7 mm. The
lesions were 2.5%, 58.4, 34.9%, and 4.2% for Class A, B1, B2 and C
respectively. At 2-year, composite endpoints of MACE, TVF, TLF of
the ﬁrst 450 patients were 6.7%, 7.4% and 6.5% respectively. Cumu-
lative scaffold thrombosis (ST) was 1.1% through 2 years, of which
0.2% was very late ST events. The 3-year follow-up data in these 450
patients represents the largest Absorb cohort with long-term safety
and performance ever reported from a single trial. Clinical outcomes
will be presented at the time of the conference.
CONCLUSION Safety and efﬁcacy of Absorb has been demonstrated in
these 450 patients through 2 years after their PCI procedure. The 3-
year clinical outcomes will provide the longest term data in the largest
single-trial cohort reported to date.INVASIVE CORONARY IMAGING: IVUS, OCT,
SPECTROSCOPY, AND OTHER (TCTAP A-003)
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BACKGROUND A large lipid core is one of characteristics of vulnerable
coronary plaque. Although optical coherence tomography (OCT) is a
very high resolution imaging device, OCT does not facilitate detection
of a lipid plaque. The reason is that while commercially-available OCT
systems use near-infrared light at 1,300 nm wavelengths, lipid shows
characteristic absorption at 1,700 nm, not at 1,300 nm (Figure).
Therefore, we developed a novel, short wavelength infrTCTAP A-red
(1,700 nm), spectroscopic optical coherence tomography (SWIR-OCT,
Sumitomo Electric Industries, Ltd.) to visualize lipid tissue automati-
cally. The aim of the present study is to investigate the accuracy of
SWIR-OCT for identiﬁcation of lipid tissue within coronary plaques.METHODS Twenty-nine coronary arteries from 10 cadavers were
examined. SWIR-OCT was performed at physiological pressure, and
the images were acquired at 94 frames/s and digitally archived. SWIR-
OCT generated gray-scale cross sectional images and color tissue maps
of a plaque by calculating the obtained spectrum with an original lipid
analysis algorithm. After SWIR-OCT imaging, the arteries were pres-
sure-ﬁxed, sliced by a cryostat and stained with H&E and Oil Red O,
and then corresponding histology was collected in matched images.
Regions of interest, selected from histology, were 108 lipidic and 16
non-lipidic regions. Lipid-enhanced images generated by SWIR-OCT
were validated by comparison with histology via selected regions.
RESULTS SWIR-OCT showed high sensitivity (90%) and speciﬁcity
(94%) for identifying lipid tissue within coronary plaques. The posi-
tive predictive value and negative predictive value were 99% and
58%, respectively.
CONCLUSION SWIR-OCT has improved the ability to detect lipid tis-
sue in coronary autopsy specimens compared with conventional OCT.
This new technique may hold promise for identifying histopatholog-
ical feature of coronary plaques at risk for rupture.
